Victoria P. Werth, M.D.

Professor of Dermatology at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center
Division Of Dermatology, University of Pennsylvania Health System (to include the Hospital of the University of Pennsylvania and Presbyterian Hospital)
Department: Dermatology
Contact information
Division of Dermatology
Veterans Administration Hospital
University and Woodland Avenues
Philadelphia, PA 19104
Veterans Administration Hospital
University and Woodland Avenues
Philadelphia, PA 19104
Office: 215-823-4208
Fax: 215-823-5171
Fax: 215-823-5171
Links
Lupus Foundation of America
International Pemphigus and Pemphigoid Foundation
Lupus Research Institute
Scleroderma Foundation
Philadelphia Dermatology Society
Medical Dermatology Society
Pennsylvania Academy of Dermatology
The Myositis Association
Lupus Foundation of America
International Pemphigus and Pemphigoid Foundation
Lupus Research Institute
Scleroderma Foundation
Philadelphia Dermatology Society
Medical Dermatology Society
Pennsylvania Academy of Dermatology
The Myositis Association
Education:
M.S. (Physical Chemistry)
Catholic University, 1976.
B.A. (Chemistry)
Catholic University, 1976.
M.D. (Medicine)
Johns Hopkins University, 1980.
Permanent linkM.S. (Physical Chemistry)
Catholic University, 1976.
B.A. (Chemistry)
Catholic University, 1976.
M.D. (Medicine)
Johns Hopkins University, 1980.
Description of Research Expertise
PhotobiologyTumor necrosis factor
Cutaneous lupus
Glycosaminoglycans
Clinical and translational research in cutaneous autoimmune diseases
Description of Clinical Expertise
Autoimmune skin diseaseCutaneous Lupus Erythematosus
Dermatomyositis
Pemphigus vulgaris
Selected Publications
Zanframundo G, Dourado E, Bauer-Ventura I, Faghihi-Kashani S, Yoshida A, Loganathan A, Rivero-Gallegos D, Lim D, Bozán F, Sambataro G, Bae SS, Yamano Y, Bonella F, Corte TJ, Doyle TJ, Fiorentino D, Gonzalez-Gay MA, Hudson M, Kuwana M, Lundberg IE, Mammen A, McHugh N, Miller FW, Montecucco C, Oddis CV, Rojas-Serrano J, Schmidt J, Selva-O'Callaghan A, Werth VP, Hansen P, Rozza D, Scirè CA, Sakellariou G, Kaneko Y, Triantafyllias K, Castañeda S, Alberti ML, Merino MGG, Fiehn C, Molad Y, Govoni M, Nakashima R, Alpsoy E, Giannini M, Chinoy H, Gallay L, Ebstein E, Campagne J, Saraiva AP, Conticini E, Sebastiani GD, Nuño-Nuño L, Scarpato S, Schiopu E, Parker M, Limonta M; CLASS project participating investigators; Cavagna L, Aggarwal R.: The role of multicriteria decision analysis in the development of candidate classification criteria for antisynthetase syndrome: analysis from the CLASS project. Ann Rheum Dis 4967(25), Mar 2025.Werth VP, Furie RA, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven RF, Nyberg F, Kaffenberger BH, Sheikh SZ, Radunovic G, Huang X, Carroll H, Naik H, Gaudreault F, Meyers A, Musselli C, Franchimont N, Barbey C.: Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary. Immunotherapy 17(3): 161-173, Feb 2025.
Fiorentino D, Mangold AR, Werth VP, Christopher-Stine L, Femia A, Chu M, Musiek ACM, Sluzevich JC, Graham LV, Fernandez AP, Aggarwal R, Rieger K, Page KM, Li X, Hyde C, Rath N, Sloan A, Oemar B, Banerjee A, Salganik M, Banfield C, Neelakantan S, Beebe JS, Vincent MS, Peeva E, Vleugels RA.: Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 405(10473): 137-146, Jan 2025.
Khosravi-Hafshejani T, Werth VP.: Serum IFNα as a Biomarker for Cutaneous Lupus: Insights into Disease Activity, Severity, Therapeutic Monitoring and Clinical Trial Application. J Invest Dermatol(25), Jan 2025.
Pandya R, Dan J, Kleitsch J, Lim D, White B, Werth VP.: Development and Evaluation of the Dermatomyositis Outcomes for Muscle and Skin as an Outcome Measure in Dermatomyositis Clinical Trials. JID Innov 5(2): 100337, Dec 2024.
Cepica TB, Gupta R, Werth VP, Chong BF.: Severity Scores for Cutaneous Lupus Erythematosus. J Invest Dermatol 144(11): 2354-2363, Nov 2024.
Nielsen W, Strand V, Simon L, Pinsker E, Bonilla D, Morand E, Thumboo J, Aringer M, Mosca M, Bruce I, Parodis I, Kim A, Desai M, Enman Y, Shea B, Wallace DJ, Chaichian Y, Navarra S, Aranow C, Mackay M, Trotter K, Tayer-Shifman OE, Duarte-García A, Shan Tam L, Ugarte-Gil MF, Pons-Estel GJ, Reynolds JA, Nikpour M, Hoi A, Romero-Diaz J, Aggarwal A, Mok CC, Fujio K, Ramsey-Goldman R, Gladman DD, Arnaud L, Bultink IEM, Ruiz-Irastorza G, Inês LS, Appenzeller S, Dobrowolski C, Clarke AE, Kamen DL, Barraclough M, Tani C, Gómez-Puerta JA, Werth VP, Katz P, Nowrouzi-Kia B, Johnson SR, Drucker AM, Touma Z; OMERACT SLE Working Group.: OMERACT systemic lupus erythematosus domain survey. Semin Arthritis Rheum Oct 2024.
Faghihi-Kashani S, Yoshida A, Bozan F, Zanframundo G, Rozza D, Loganathan A, Dourado E, Sambataro G, Ventura IB, Bae SS, Lim D, Gallegos DR, Yamano Y, Selva-O'Callaghan A, Mammen AL, Scirè CA, Montecucco C, Oddis CV, Fiorentino D, Bonella F, Miller FW, Lundberg IE, Schmidt J, Rojas-Serrano J, Hudson M, Kuwana M, González-Gay MA, McHugh N, Corte TJ, Doyle TJ, Werth VP, Gupta L, Roman DIP, Bianchessi LM, Devarasetti PK, Shinjo SK, Luppi F, Cavazzana I, Moghadam-Kia S, Fornaro M, Volkmann ER, Piga M, Loarce-Martos J, De Luca G, Knitza J, Wolff-Cecchi V, Sebastiani M, Schiffenbauer A, Rider LG, Campanilho-Marques R, Marts L, Bravi E, Gunawardena H; CLASS project participating investigators; Aggarwal R, Cavagna L.: Clinical Characteristics of Anti-Synthetase Syndrome: Analysis from the CLASS project. Arthritis Rheumatol Oct 2024.
Murrell DF, Caux F, Patsatsi A, Hagino O, Rudnicka L, Vassileva S, Uzun S, Ye J, Yen K, Arora P, Gourlay SG, Joly P, Werth VP.: Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study. J Invest Dermatol 144(8): 1762-1771, Aug 2024.
Pandya R, Kleitsch J, Lim D, Werth VP.: Clinical characteristics and symptom progression of dermatomyositis subtypes: A retrospective analysis of a prospective database. J Am Acad Dermatol 91(1): 31-36, Jul 2024.